Newsroom

News Releases

Filter News Releases by year:
2022 | 2021 | 2020 | 2019 | 2018
547 Results

December 2022

Ebola Vaccine Regimens Safe, Immunogenic in Adults and Children

December 14, 2022

Two randomized, placebo-controlled trials evaluating three Ebola vaccine administration strategies in adults and children found that all the regimens were safe in both age groups, according to results published today in the New England Journal of Medicine. Antibodies were produced in response to the vaccine regimens beginning at 14 days after the first vaccination and continued to be detectable at varying levels—depending on the vaccine and regimen used—in both children and adults for one year.

colorized scanning electron micrograph of Ebola virus particles (green) on the surface of infected cells (orange).

NIH Statement on World AIDS Day

December 01, 2022

In the 34 years since the first observance of World AIDS Day, transformational progress has been made in the global fight against HIV/AIDS, yet challenges remain. Today, we at the National Institutes of Health reflect on the 40 million lives lost to the disease and renew our commitment to the research necessary to end the global pandemic.  

Red AIDS Awareness Ribbon and white Pin of Remembrance

November 2022

Dr. Fauci Reflects on the Perpetual Challenge of Infectious Diseases

November 28, 2022

Once considered a potentially static field of medicine, the discipline of studying infectious diseases has proven to be dynamic as emerging and reemerging infectious diseases present continuous challenges, Anthony S. Fauci, M.D., writes in a perspective in The New England Journal of Medicine. In the piece, Dr. Fauci, who since 1984 has directed the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, reflects on his career responding to infectious disease threats. Dr.

A black and white photo of Dr. Fauci standing with arms crossed in front of a wall with various plaques and frames

NIH Awards $12 Million for Antiviral Therapeutic Development

November 21, 2022

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, recently awarded more than $12 million to three institutions for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential. NIAID may award approximately $61.5 million total over five years if all contract options are exercised.

Snake-like blue Ebola virus particle on red background

Experimental Cancer Vaccine Shows Promise in Animal Studies

November 10, 2022

An experimental therapeutic cancer vaccine induced two distinct and desirable immune system responses that led to significant tumor regression in mice, report investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.  

T cell shown in a colorized scanning micrograph

October 2022

Monoclonal Antibody Prevents Malaria Infection in African Adults

October 31, 2022

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found. The antibody was up to 88.2% effective at preventing infection over a 24-week period, demonstrating for the first time that a monoclonal antibody can prevent malaria infection in an endemic region.

Illustration shows antibody drug prevents malaria infection by interrupting lifecycle of P. falciparum

Experimental Monoclonal Antibodies Show Promise Against Epstein-Barr Virus

October 27, 2022

A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) blocked infection when tested in human cells in a laboratory setting. Moreover, one of the experimental mAbs provided nearly complete protection against EBV infection and lymphoma when tested in mice. The results appear online today in the journal Immunity.

An electron microscopy image showing three Epstein-Barr virions.

Early HIV diagnosis and treatment important for better long-term health outcomes

October 21, 2022

Starting antiretroviral treatment (ART) early in the course of HIV infection when the immune system is stronger results in better long-term health outcomes compared with delaying ART, according to findings presented today at the IDWeek Conference in Washington, D.C.

Image of antiretroviral drugs

Three-dose hepatitis B vaccine regimen protects people with HIV

October 20, 2022

A three-dose course of the hepatitis B vaccine HEPLISAV-B fully protected adults living with HIV who had never been vaccinated against or infected with the hepatitis B virus (HBV), according to study findings presented today at the IDWeek conference in Washington, D.C. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsors the ongoing Phase 3 ACTG A5379 clinical study.

Image of Hepatitis B virus particles

Monkeypox Treatment Trial Begins in the Democratic Republic of the Congo

October 12, 2022

A clinical trial to evaluate the antiviral drug tecovirimat, also known as TPOXX, in adults and children with monkeypox has begun in the Democratic Republic of the Congo (DRC). The trial will evaluate the drug’s safety and its ability to mitigate monkeypox symptoms and prevent serious outcomes, including death. The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S.

Monkeypox virus (orange circles) on green background.

Monoclonal Antibody Improves Cat Allergen Immunotherapy

October 11, 2022

An experimental approach to enhancing a standard cat allergy treatment made it more effective and faster acting, and the benefits persisted for a year after treatment ended, a study supported by the National Institutes of Health has found. The findings were published Monday in the Journal of Allergy and Clinical Immunology. 

a white and gray cat

Findings Suggest COVID-19 Rebound Not Caused by Impaired Immune Response

October 06, 2022

Findings from a small study of eight patients published in Clinical Infectious Diseases suggest that COVID-19 rebound is likely not caused by impaired immune responses. The study, led by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, aimed to define the clinical course and the immunologic and virologic characteristics of COVID-19 rebound in patients who have taken nirmatrelvir/ritonavir (Paxlovid), an antiviral therapeutic developed by Pfizer, Inc.

Colorized scanning electron micrograph of a cell infected with the Omicron strain of SARS-CoV-2 virus particles (pink)

NIH-Supported Clinical Trial of Phage Therapy for Cystic Fibrosis Begins

October 04, 2022

Enrollment has begun in an early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis (CF) who carry Pseudomonas aeruginosa (P. aeruginosa) in their lungs. The trial is evaluating whether the bacteriophage, or “phage,” therapy is safe and able to reduce the amount of bacteria in the lungs of volunteers. The trial is being conducted by the Antibacterial Resistance Leadership Group (ARLG), funded by the National Institute of Allergy and Infectious Diseases.

A digitally-colorized scanning electron microscopic image shows a number of rod-shaped Pseudomonas aeruginosa bacteria (colored pink).

September 2022

U.S. Clinical Trial Evaluating Antiviral for Monkeypox Begins

September 09, 2022

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. Study investigators aim to enroll more than 500 people from clinical research sites nationwide. Interested volunteers can visit the ACTG website (clinical trial A5418) for more information.

Clinical Trial Evaluating Monkeypox Vaccine Begins

September 08, 2022

A clinical trial evaluating alternative strategies for administering the JYNNEOS monkeypox vaccine to increase the number of available doses has begun enrolling adult volunteers. The trial, which will enroll more than 200 adults across eight U.S. research sites, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. JYNNEOS is manufactured by Bavarian Nordic, based in Copenhagen. It is approved by the U.S.

Monkeypox particles (green) found within an infected cell (pink and purple)

August 2022

SARS-CoV-2 Antigen Levels Linked to Patient Outcomes

August 29, 2022

The amount of SARS-CoV-2 antigen measured in the blood of patients hospitalized with COVID-19 is associated with illness severity and other clinical outcomes, according to a new study published in the Annals of Internal Medicine.

A transmission electron micrograph of SARS-CoV-2 virus particles (colored gold) within the endosomes of a heavily infected nasal olfactory epithelial cell.

NIH Experts Review Monkeypox Challenges

August 24, 2022

Lessons learned from the public health responses to the HIV and COVID-19 pandemics should help guide the response to the current outbreak of monkeypox, National Institutes of Health experts write in an editorial published today in the New England Journal of Medicine. Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), and H.

red circular monkeypox virus particles on a blue backdrop

Statement by Anthony S. Fauci, M.D.

August 22, 2022

I am announcing today that I will be stepping down from the positions of Director of the National Institute of Allergy and Infectious Diseases (NIAID) and Chief of the NIAID Laboratory of Immunoregulation, as well as the position of Chief Medical Advisor to President Joe Biden. I will be leaving these positions in December of this year to pursue the next chapter of my career.

Monoclonal Antibody Reduces Asthma Attacks in Urban Youth

August 10, 2022

A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma, are prone to asthma attacks and live in low-income urban neighborhoods, a National Institutes of Health clinical trial has found. This population has been underrepresented in previous clinical trials of asthma therapeutics. The findings were published today in the journal The Lancet.

Illustration of Black or Hispanic child using asthma inhaler

Monoclonal Antibody Prevents Malaria in U.S. Adults, NIH Trial Shows

August 04, 2022

One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National Institutes of Health Phase 1 clinical trial published in The New England Journal of Medicine.

This image shows the lifecycle of the malaria parasite in a person.

NIH Updates Hepatitis B Strategic Research Plan

August 01, 2022

The National Institutes of Health has updated its Strategic Plan for NIH Research to Cure Hepatitis B, a roadmap for ending the hepatitis B epidemic, focused on developing a cure as well as improved strategies for vaccination, screening and follow-up care. The revised plan incorporates lessons from the COVID-19 pandemic and recent advances in technology.

A transmission electron microscopic (TEM) image showing clusters of round hepatitis B viral particles, colored orange.

July 2022

New Insights into HIV Latent Cells Yield Potential Cure Targets

July 27, 2022

In a presentation today at AIDS 2022, the 24th International AIDS Conference in Montreal, scientists with the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) and their collaborators described how their use of cutting-edge technology revealed new insights into cellular reservoirs of HIV and what those observations could mean for the next steps in HIV cure research. NIAID is part of the National Institutes of Health.

Scanning electron micrograph of an HIV-infected H9 T cell.

Statement from NIH and BARDA on the Novavax COVID-19 Vaccine

July 20, 2022

The Centers for Disease Control and Prevention (CDC) has recommended that Novavax’s COVID-19 vaccine be used as another primary series option for adults in the United States ages 18 years and older. The Food and Drug Administration (FDA) previously authorized for emergency use the protein-based vaccine, known as NVX-CoV2373. 

Vaccine-Induced Immune Response to Omicron Wanes Substantially Over Time

July 19, 2022

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substantially within 3 months, according to new clinical trial data. The findings, published today in Cell Reports Medicine, are from a study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial was led by NIAID’s Infectious Diseases Clinical Research Consortium. 

A table showing the COVID-19 vaccine combinations from the “mix & match” study evaluated in this report.

NIH Launches Clinical Trial of mRNA Nipah Virus Vaccine

July 11, 2022

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an investigational vaccine to prevent infection with Nipah virus. The experimental vaccine is manufactured by Moderna, Inc., (Cambridge, Massachusetts) and was developed in collaboration with NIAID’s Vaccine Research Center. It is based on a messenger RNA (mRNA) platform—a technology used in several approved COVID-19 vaccines.

Colorized transmission electron micrograph of mature extracellular Nipah Virus particles (red) near the periphery of an infected VERO cell (green).